Literature DB >> 19228923

Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting.

Antonina V Kurtova1, Archito T Tamayo, Richard J Ford, Jan A Burger.   

Abstract

Mantle cell lymphoma (MCL) is characterized by an early, widespread dissemination and residual disease after conventional treatment, but the mechanisms responsible for lymphoma cell motility and drug resistance are largely unknown. There is growing evidence suggesting that chemokine receptors and adhesion molecules are critical for malignant B-cell trafficking and homing to supportive tissue microenvironments, where they receive survival and drug resistance signals. Therefore, we examined chemokine receptor and adhesion molecule expression and function in MCL cells and their importance for migration and adhesion to marrow stromal cells (MSCs). We found that MCL cells display high levels of functional CXCR4 and CXCR5 chemokine receptors and VLA-4 adhesion molecules. We also report that MCL cells adhere and spontaneously migrate beneath MSCs in a CXCR4- and VLA-4-dependent fashion (pseudoemperipolesis). Moreover, we demonstrate that MSCs confer drug resistance to MCL cells, particularly to MCL cells that migrate beneath MSC. To target MCL-MSC interactions, we tested Plerixafor, a CXCR4 antagonist, and natalizumab, a VLA-4 antibody. Both agents blocked functional responses to the respective ligands and inhibited adhesive interactions between MCL cells and MSCs. These findings provide a rationale to further investigate the therapeutic potential of these drugs in MCL.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19228923      PMCID: PMC4969050          DOI: 10.1182/blood-2008-10-185827

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  54 in total

1.  Balanced responsiveness to chemoattractants from adjacent zones determines B-cell position.

Authors:  Karin Reif; Eric H Ekland; Lars Ohl; Hideki Nakano; Martin Lipp; Reinhold Förster; Jason G Cyster
Journal:  Nature       Date:  2002-03-07       Impact factor: 49.962

2.  Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling.

Authors:  Richard J Byers; Ebrahim Sakhinia; Preethi Joseph; Caroline Glennie; Judith A Hoyland; Lia P Menasce; John A Radford; Timothy Illidge
Journal:  Blood       Date:  2008-01-03       Impact factor: 22.113

3.  Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro.

Authors:  P Panayiotidis; D Jones; K Ganeshaguru; L Foroni; A V Hoffbrand
Journal:  Br J Haematol       Date:  1996-01       Impact factor: 6.998

4.  Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells.

Authors:  Meike Burger; Tanja Hartmann; Myriam Krome; Justyna Rawluk; Hirokazu Tamamura; Nobutaka Fujii; Thomas J Kipps; Jan A Burger
Journal:  Blood       Date:  2005-05-19       Impact factor: 22.113

5.  Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL).

Authors:  Pedro Farinha; Hamid Masoudi; Brian F Skinnider; Karey Shumansky; John J Spinelli; Karamjit Gill; Richard Klasa; Nicolas Voss; Joseph M Connors; Randy D Gascoyne
Journal:  Blood       Date:  2005-06-02       Impact factor: 22.113

6.  CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential.

Authors:  Tait D Shanafelt; Susan M Geyer; Nancy D Bone; Renee C Tschumper; Tom E Witzig; Greg S Nowakowski; Clive S Zent; Tim G Call; Betsy Laplant; Gordon W Dewald; Diane F Jelinek; Neil E Kay
Journal:  Br J Haematol       Date:  2008-03       Impact factor: 6.998

7.  Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomas.

Authors:  Livio Trentin; Anna Cabrelle; Monica Facco; Davide Carollo; Marta Miorin; Alicia Tosoni; Paola Pizzo; Gianni Binotto; Linda Nicolardi; Renato Zambello; Fausto Adami; Carlo Agostini; Gianpietro Semenzato
Journal:  Blood       Date:  2004-03-04       Impact factor: 22.113

8.  Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell-derived factor-1- and CD106 (VCAM-1)-dependent mechanism.

Authors:  J A Burger; N J Zvaifler; N Tsukada; G S Firestein; T J Kipps
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

9.  A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study.

Authors:  R I Fisher; S Dahlberg; B N Nathwani; P M Banks; T P Miller; T M Grogan
Journal:  Blood       Date:  1995-02-15       Impact factor: 22.113

10.  Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5.

Authors:  Christopher D C Allen; K Mark Ansel; Caroline Low; Robin Lesley; Hirokazu Tamamura; Nobutaka Fujii; Jason G Cyster
Journal:  Nat Immunol       Date:  2004-08-01       Impact factor: 25.606

View more
  73 in total

Review 1.  The host-tumor interface in B-cell non-Hodgkin lymphoma: a new world to investigate.

Authors:  Nicolas Rachinel; Gilles Salles
Journal:  Curr Hematol Malig Rep       Date:  2009-10       Impact factor: 3.952

Review 2.  Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.

Authors:  Patricia Pérez-Galán; Martin Dreyling; Adrian Wiestner
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

3.  ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy.

Authors:  Zheng Chen; Albert E Teo; Nami McCarty
Journal:  Clin Cancer Res       Date:  2015-09-08       Impact factor: 12.531

4.  The membrane-proximal KXGFFKR motif of α-integrin mediates chemoresistance.

Authors:  Chi-Chao Liu; Pascal Leclair; Shyong Quin Yap; Chinten James Lim
Journal:  Mol Cell Biol       Date:  2013-09-03       Impact factor: 4.272

Review 5.  The microenvironment in mature B-cell malignancies: a target for new treatment strategies.

Authors:  Jan A Burger; Paolo Ghia; Andreas Rosenwald; Federico Caligaris-Cappio
Journal:  Blood       Date:  2009-07-27       Impact factor: 22.113

6.  Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance.

Authors:  Marek Mraz; Clive S Zent; Amy K Church; Diane F Jelinek; Xiaosheng Wu; Sarka Pospisilova; Stephen M Ansell; Anne J Novak; Neil E Kay; Thomas E Witzig; Grzegorz S Nowakowski
Journal:  Br J Haematol       Date:  2011-07-12       Impact factor: 6.998

7.  Serum levels of the chemokine CXCL13, genetic variation in CXCL13 and its receptor CXCR5, and HIV-associated non-hodgkin B-cell lymphoma risk.

Authors:  Shehnaz K Hussain; Weiming Zhu; Shen-Chih Chang; Elizabeth Crabb Breen; Elena Vendrame; Larry Magpantay; Dan Widney; Daniel Conn; Mary Sehl; Lisa P Jacobson; Jay H Bream; Steven Wolinsky; Charles R Rinaldo; Richard F Ambinder; Roger Detels; Zuo-Feng Zhang; Otoniel Martínez-Maza
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-12-18       Impact factor: 4.254

8.  Role of chemokine network in the development and progression of ovarian cancer: a potential novel pharmacological target.

Authors:  Federica Barbieri; Adriana Bajetto; Tullio Florio
Journal:  J Oncol       Date:  2009-12-14       Impact factor: 4.375

9.  New developments in the pathology of malignant lymphoma: a review of the literature published from January to August 2009.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2009-09-26       Impact factor: 0.196

Review 10.  Mesenchymal stem cells as a double-edged sword in suppression or progression of solid tumor cells.

Authors:  Fatemeh Norozi; Ahmad Ahmadzadeh; Saeid Shahrabi; Tina Vosoughi; Najmaldin Saki
Journal:  Tumour Biol       Date:  2016-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.